TST (Ag4O4) Clinical Experiments Show Silver Compound Can Help AIDS Patients: Researchers Say Silver Oxide Offsets AIDS Loss of Immune Response

Clinical Experiments Show Silver Compound Can Help AIDS Patients: Researchers Say Silver Oxide Offsets AIDS Loss of Immune Response


By Samuel Etris, Senior Technical Consultant to The Silver Institute


One dose of silver oxide may prolong the life of terminally ill patients suffering from AIDS, according to a study conducted at an AIDS clinic in Central America. The triple-charged silver in silver oxide appears to significantly increase the effectiveness of silver in combating disease-prone bacteria and viruses that rage through an AIDS-infected patient. This action of silver offsets the loss of the body's bacteria-fighting immune system caused by the AIDS virus.

The ten patients classified as terminally ill at The Struggle Against AIDS Clinic, Comayaguela, Honduras, were treated with polyvalent silver oxide. The ten patients fell into two of the major AIDS categories: Wasting Syndrome and Candidasis, which covers approximately one third of all AIDS cases.

Before the administration of one single dose of polyvalent silver oxide (approximately 40 parts per million of blood volume), the patients were removed from the standard AZT therapy. Following the administration of polyvalent silver oxide, eight out of nine patients showed an increase in their white blood count from 10 to 350 percent. Then they were treated with the standard Antibiotics .

Two of the patients had conditions so far advanced that they were unresponsive to the subsequent treatment and succumbed within a year. However, the single treatment appeared to prolong the lives of the eight remaining patients as much as three years. This single experiment shows the promise for the polyvalent silver oxide regimen.

Further research is needed to investigate the optimal modes of administration and dosages of the polyvalent silver oxide for AIDS therapy. Additional clinical trials are now being organized in South Africa to gain more data on its potential.

For more than a century, single-charged silver has been a proven barrier against blindness in babies' eyes exposed to disease during birth. The single-charged silver replaces the working hydrogen atoms of bacteria and extracellular viruses that supply the energy to function. Blocking the energy supply inactivates them. The more powerful triple-charged silver in polyvalent silver oxide signals new potential in combating disease.

In one laboratory experiment, polyvalent silver oxide in as little a concentration as 20 parts per million inserted into cultured HIV-1 infected cells resulted in a 98.4-percent kill. This breakthrough, reported by the National Virology Laboratory of Israel at Tel HaShomer, encouraged the Kaplan Hospital, Rehovot, Israel, to conduct a study of laboratory mice infected with Murine AIDS. A single administration of 40 parts per million of polyvalent silver oxide (Ag4O4) reportedly resulted in an effective cure.

These early experiments with AIDS infections indicate that polyvalent silver oxide may be more than merely a multi-spectrum Antibiotic inactivating a whole range of bacteria, such as candida albicans, that ravage the AIDS-weakened immune system. Further studies may reveal that silver also stimulates the body's immune system to restore at least some of its normal function, aiding in the patient's recovery.

For nearly a decade, Antelman Technologies, Inc., Rehovot, Israel, has been conducting laboratory and clinical studies to determine the effectiveness of polyvalent silver oxide for a wide variety of applications. Currently it is available over the counter as the EPA-approved product Sildate, which replaces chlorine in swimming pools, U.S. patents for which have been assigned to the supplier, N. Jonas & Co. in Bensalem, Pennsylvania.

The buffer to bring polyvalent silver oxide into an injectable solution for clinical evaluation is supplied by Holipharm Corp., in Jerusalem, which has received the assignment of all rights of U.S. patents for (Ag4O4) AIDS studies under the trade name Tetrasil.

Silver News - February/March 1998

original text::
http://www.silverinstitute.org/news/2a1998.htm

http://www.silverinstitute.org/news/2a1998.htm

Tweet